Relative Value Partners Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Relative Value Partners Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$777K	Buy	+1,657	New	+$719K	0.1%	171

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Relative Value Partners Group's VRTX Position: Q2 2024 in Review

Relative Value Partners Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2024: 1,657 shares worth $777K. The stake represents 0.1% of the portfolio and ranks #171 among its holdings.

1,549 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

Relative Value Partners Group held 1,657 shares of Vertex Pharmaceuticals worth $777K as of Q2 2024.
Vertex Pharmaceuticals was a new Relative Value Partners Group position in Q2 2024.
Vertex Pharmaceuticals made up 0.1% of Relative Value Partners Group's portfolio in Q2 2024, its #171 holding.
1,549 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Relative Value Partners Group's 13F filing for Q2 2024, filed 12 Jul 2024.